Pacer Advisors
RARE icon

Pacer Advisors’s Ultragenyx Pharmaceutical RARE Stock Holding History

Pacer Advisors’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-718
Closed -$29.5K – 2666
2024
Q2 		$29.5K Sell
718
-122
-15% -$5.21K ﹤0.01% 3347
2024
Q1 		$39.2K Buy
+840
New +$39.6K ﹤0.01% 3267
2021
Q2 		– Sell
-609
Closed -$69K – 1526
2021
Q1 		$69K Sell
609
-296
-33% -$40.3K ﹤0.01% 1384
2020
Q4 		$125K Sell
905
-638
-41% -$75.7K ﹤0.01% 1329
2020
Q3 		$127K Buy
+1,543
New +$128K ﹤0.01% 1226
2018
Q4 		– Sell
-2,910
Closed -$222K – 932
2018
Q3 		$222K Buy
+2,910
New +$237K 0.01% 1013
2018
Q1 		– Sell
-1,100
Closed -$51K – 1110
2017
Q4 		$51K Buy
+1,100
New +$53.9K ﹤0.01% 1009
2017
Q3 		– Sell
-3,402
Closed -$211K – 1242
2017
Q2 		$211K Buy
3,402
+365
+12% +$22K 0.02% 984
2017
Q1 		$206K Buy
3,037
+560
+23% +$42.7K 0.03% 905
2016
Q4 		$174K Buy
2,477
+240
+11% +$17K 0.02% 914
2016
Q3 		$159K Buy
2,237
+192
+9% +$12.3K 0.02% 900
2016
Q2 		$100K Buy
+2,045
New +$132K 0.02% 987

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Pacer Advisors's RARE Position: Q3 2024 in Review

Pacer Advisors sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2024, closing a stake of 718 shares — an estimated $29.5K sold.

Pacer Advisors first reported a position in RARE in Q2 2016 and held it in 12 quarters. The position peaked at $222K in Q3 2018. 300 funds tracked by Wall St. Rank hold RARE as of Q3 2024.

  • Pacer Advisors reported no remaining Ultragenyx Pharmaceutical position as of Q3 2024 after selling out during the quarter.
  • Pacer Advisors sold 718 Ultragenyx Pharmaceutical shares in Q3 2024, an estimated $29.5K.
  • Pacer Advisors first reported a position in Ultragenyx Pharmaceutical in Q2 2016 and held it in 12 quarters.
  • Pacer Advisors's Ultragenyx Pharmaceutical position peaked at $222K in Q3 2018.
  • 300 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2024.

Based on Pacer Advisors's 13F filing for Q3 2024, filed 12 Nov 2024.